{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:40:47Z","timestamp":1790005247224,"version":"4.0.1"},"reference-count":30,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:p>\n                    <jats:sup>44<\/jats:sup>\n                    Sc is a promising positron emission tomography (PET) radionuclide (T\n                    <jats:sub>1\/2<\/jats:sub>\n                    \u2009=\u20094.04 hours, E\n                    <jats:sub>\u03b2+average<\/jats:sub>\n                    \u2009=\u2009632\u2009keV) and can be made available, using a cyclotron production route, in substantial quantities as a highly pure product. Herein, the authors report on a first-in-human PET\/CT study using\n                    <jats:sup>44<\/jats:sup>\n                    Sc-DOTATOC prepared with cyclotron-produced\n                    <jats:sup>44<\/jats:sup>\n                    Sc. The production of\n                    <jats:sup>44<\/jats:sup>\n                    Sc was carried out through the\n                    <jats:sup>44<\/jats:sup>\n                    Ca(p,n)\n                    <jats:sup>44<\/jats:sup>\n                    Sc nuclear reaction at Paul Scherrer Institut, Switzerland. After separation,\n                    <jats:sup>44<\/jats:sup>\n                    Sc was shipped to Zentralklinik Bad Berka, Germany, where radiolabeling was performed, yielding radiochemically pure\n                    <jats:sup>44<\/jats:sup>\n                    Sc-DOTATOC. Two patients, currently followed up after peptide receptor radionuclide therapy of metastatic neuroendocrine neoplasms, participated in this proof-of-concept study. Blood sampling was performed before and after application of\n                    <jats:sup>44<\/jats:sup>\n                    Sc-DOTATOC. PET\/CT acquisitions, performed at different time points after injection of\n                    <jats:sup>44<\/jats:sup>\n                    Sc-DOTATOC, allowed detection of even very small lesions on delayed scans. No clinical adverse effects were observed and the laboratory hematological, renal, and hepatic profiles remained unchanged. In this study, cyclotron-produced\n                    <jats:sup>44<\/jats:sup>\n                    Sc was used in the clinic for the first time. It is attractive for theranostic application with\n                    <jats:sup>177<\/jats:sup>\n                    Lu,\n                    <jats:sup>90<\/jats:sup>\n                    Y, or\n                    <jats:sup>47<\/jats:sup>\n                    Sc as therapeutic counterparts.\n                    <jats:sup>44<\/jats:sup>\n                    Sc-based radiopharmaceuticals will be of particular value for PET facilities without radiopharmacy, to which they can be shipped from a centralized production site.\n                  <\/jats:p>","DOI":"10.1089\/cbr.2016.2173","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T16:19:11Z","timestamp":1495037951000},"page":"124-132","source":"Crossref","is-referenced-by-count":45,"title":["First-in-Human PET\/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced\n                    <sup>44<\/sup>\n                    Sc-DOTATOC: A Proof-of-Concept Study"],"prefix":"10.1177","volume":"32","author":[{"given":"Aviral","family":"Singh","sequence":"first","affiliation":[{"name":"ENETS Center of Excellence","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"van der Meulen","sequence":"additional","affiliation":[{"name":"Laboratory of Radiochemistry","place":["Switzerland"]},{"name":"Center for Radiopharmaceutical Sciences ETH-PSI-USZ","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Center for Radiopharmaceutical Sciences ETH-PSI-USZ","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Klette","sequence":"additional","affiliation":[{"name":"ENETS Center of Excellence","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshad R.","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"ENETS Center of Excellence","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"T\u00fcrler","sequence":"additional","affiliation":[{"name":"Laboratory of Radiochemistry","place":["Switzerland"]},{"name":"Department of Chemistry and Biochemistry University of Bern","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Schibli","sequence":"additional","affiliation":[{"name":"Center for Radiopharmaceutical Sciences ETH-PSI-USZ","place":["Switzerland"]},{"name":"Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[{"name":"ENETS Center of Excellence","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,5,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1039\/c0dt01504k"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2015.05.005"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2015.12.007"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2010.11.003"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.141614"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2014.12.020"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2015.04.012"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.5603\/NMR.2011.00021"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2012.03.005"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-016-0013-5"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2012.08.004"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp500343j"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-012-0561-3"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.123810"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-017-0257-4"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/bc500415x"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2016.01.006"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2012.04.030"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1524\/ract.2013.2032"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2010.04.003"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1512-3"},{"key":"e_1_3_3_23_2","unstructured":"Radiation Protection in Medicine. Directive on the Ordinance on the Protection against Damage and Injuries Caused by Ionizing Radiation. (Radiation Protection Ordinance StrlSchV). Gemeinsames Ministerialblatt (GMBl) November 30 2011 No. 44\u201347: 867. Online document at www.bmub.bund.de\/N5613-1\/"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.163865"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-015-3882-1"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1205-y"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.114165"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.120600"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20010601)92:5<628::AID-IJC1244>3.0.CO;2-L"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100497"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-2003-x"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2016.2173","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2016.2173","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2016.2173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:14:40Z","timestamp":1777385680000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2016.2173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1089\/cbr.2016.2173"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2016.2173","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}